Pfizer Total Liabilities 2012-2026 | PFE
Pfizer total liabilities from 2012 to 2026. Total liabilities can be defined as the total value of all possible claims against the corporation.
- Pfizer total liabilities for the quarter ending June 30, 2026 were $115.639B, a 1.23% decline year-over-year.
- Pfizer total liabilities for 2025 were $121.385B, a 2.81% decline from 2024.
- Pfizer total liabilities for 2024 were $124.899B, a 8.97% decline from 2023.
- Pfizer total liabilities for 2023 were $137.213B, a 35.47% increase from 2022.
|
Pfizer Annual Total Liabilities (Millions of US $) |
|
|---|---|
| 2025 | $121,385 |
| 2024 | $124,899 |
| 2023 | $137,213 |
| 2022 | $101,288 |
| 2021 | $104,013 |
| 2020 | $90,756 |
| 2019 | $104,148 |
| 2018 | $95,664 |
| 2017 | $100,141 |
| 2016 | $111,776 |
| 2015 | $102,384 |
| 2014 | $95,944 |
| 2013 | $95,481 |
| 2012 | $104,120 |
| 2011 | $105,381 |
|
Pfizer Quarterly Total Liabilities (Millions of US $) |
|
|---|---|
| 2026-06-30 | $115,639 |
| 2026-03-31 | $117,214 |
| 2025-12-31 | $121,385 |
| 2025-09-30 | $115,635 |
| 2025-06-30 | $117,083 |
| 2025-03-31 | $117,391 |
| 2024-12-31 | $124,899 |
| 2024-09-30 | $126,918 |
| 2024-06-30 | $128,218 |
| 2024-03-31 | $128,537 |
| 2023-12-31 | $137,213 |
| 2023-09-30 | $117,817 |
| 2023-06-30 | $120,875 |
| 2023-03-31 | $94,381 |
| 2022-12-31 | $101,288 |
| 2022-09-30 | $102,459 |
| 2022-06-30 | $107,821 |
| 2022-03-31 | $101,155 |
| 2021-12-31 | $104,013 |
| 2021-09-30 | $103,221 |
| 2021-06-30 | $99,605 |
| 2021-03-31 | $89,953 |
| 2020-12-31 | $90,756 |
| 2020-09-30 | $113,487 |
| 2020-06-30 | $113,370 |
| 2020-03-31 | $100,998 |
| 2019-12-31 | $104,148 |
| 2019-09-30 | $105,051 |
| 2019-06-30 | $96,274 |
| 2019-03-31 | $96,263 |
| 2018-12-31 | $95,664 |
| 2018-09-30 | $96,174 |
| 2018-06-30 | $94,856 |
| 2018-03-31 | $94,071 |
| 2017-12-31 | $100,141 |
| 2017-09-30 | $111,041 |
| 2017-06-30 | $109,863 |
| 2017-03-31 | $110,038 |
| 2016-12-31 | $111,776 |
| 2016-09-30 | $114,829 |
| 2016-06-30 | $107,592 |
| 2016-03-31 | $99,582 |
| 2015-12-31 | $102,384 |
| 2015-09-30 | $103,743 |
| 2015-06-30 | $93,698 |
| 2015-03-31 | $93,053 |
| 2014-12-31 | $95,944 |
| 2014-09-30 | $93,057 |
| 2014-06-30 | $95,656 |
| 2014-03-31 | $93,740 |
| 2013-12-31 | $95,481 |
| 2013-09-30 | $97,167 |
| 2013-06-30 | $100,358 |
| 2013-03-31 | $104,571 |
| 2012-12-31 | $104,120 |
| 2012-09-30 | $100,488 |
| 2012-06-30 | $102,881 |
| 2012-03-31 | $102,006 |
| 2011-12-31 | $105,381 |
| 2011-09-30 | $105,602 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $157.539B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1084.858B | 36.60 |
| Johnson & Johnson (JNJ) | United States | $651.203B | 24.88 |
| AbbVie (ABBV) | United States | $466.469B | 24.29 |
| Merck (MRK) | United States | $363.044B | 45.84 |
| Roche Holding AG (RHHBY) | Switzerland | $348.022B | 0.00 |
| Novartis AG (NVS) | Switzerland | $268.897B | 16.24 |
| Novo Nordisk (NVO) | Denmark | $192.843B | 10.74 |
| Sanofi (SNY) | France | $104.590B | 8.80 |
| Bayer (BAYRY) | Germany | $55.531B | 9.88 |
| Innoviva (INVA) | United States | $1.521B | 5.20 |